文献速递骨质疏松与代谢性骨病创伤骨科

罗莫佐单抗在老年人中的真实世界应用:骨折联络服务队列模式

Romosozumab in older adults: real-world patterns in fracture liaison service cohort.
PubMed 文献 · Osteoporos Int · 2026-08-11

该回顾性单中心队列研究描述了在骨折联络服务(FLS)中启动罗莫佐单抗及其他骨质疏松治疗的老年人基线特征与12个月计划治疗完成率。罗莫佐单抗组基线骨折风险更高,但12个月计划治疗完成率达100%,显著高于特立帕肽组的52.9%(p=0.016)。短期临床轨迹组间无显著差异,支持罗莫佐单抗在高危患者中的常规应用。

要点

  • 罗莫佐单抗组基线骨折风险高于抗骨吸收治疗组,反映基于适应症的处方模式。
  • 12个月计划治疗完成率:罗莫佐单抗、地舒单抗、唑来膦酸均为100%,特立帕肽为52.9%。
  • 罗莫佐单抗与特立帕肽完成率差异经Holm校正后仍显著(p=0.016)。

核心结论

  • 在老年FLS队列中,罗莫佐单抗接受者风险表型更高,但12个月临床轨迹与其他治疗 broadly 相似。
  • 每月一次罗莫佐单抗显示高12个月治疗完成率,支持其作为极高风险患者的实用选择。

研究设计与样本

  • 回顾性、单中心观察性队列研究,于2022-2024年在Hospital Universitario de Navarra的FLS进行。
  • 按日历时间(同月±3个月)为每例罗莫佐单抗患者匹配1例其他治疗患者。

主要发现

  • 基线特征组间不同,符合基于适应症的处方;估测骨折风险(FRAX/QFracture)在合成代谢治疗组更高。
  • 12个月计划治疗完成率:地舒单抗、罗莫佐单抗、唑来膦酸均为100%,特立帕肽为52.9%。
  • 罗莫佐单抗与特立帕肽完成率差异经Holm校正后仍显著(p=0.016)。
  • 随访期间新发骨折和药物不良反应不频繁,死亡率、急诊就诊、入院、跌倒、骨折或药物不良反应组间无显著差异。
  • 12个月治疗序贯方案组间显著不同,罗莫佐单抗和特立帕肽后方案异质。

关键数值与推荐

  • 纳入标准:基线前24个月内≥1次脆性骨折(即将面临骨折风险)并启动罗莫佐单抗的患者。
  • 12个月计划治疗完成率:罗莫佐单抗100%,特立帕肽52.9%,组间比较p=0.016(Holm校正)。

临床怎么用

  • 对于极高骨折风险的老年患者,罗莫佐单抗可作为实用治疗选择,每月给药有利于提高治疗完成率。
  • 需注意罗莫佐单抗后的治疗序贯方案存在异质性,应根据个体情况制定后续治疗。

局限性

  • 单中心研究,结果外推需谨慎。
  • 需更大规模研究确定比较有效性和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Evidence on romosozumab use in very old adults managed in FLS remains limited. In this descriptive real-world cohort, patients receiving romosozumab had a higher baseline fracture risk phenotype than those receiving antiresorptive therapies, reflecting indication-based prescribing in routine care. Monthly romosozumab showed high 12-month scheduled-treatment completion, whereas completion was lower with daily administered teriparatide. These findings, although exploratory, support the use of romosozumab as a practical option for patients at very high risk. PURPOSE: To describe baseline treatment-allocation profiles and 12-month scheduled-treatment completion among older adults initiating romosozumab and other osteoporosis therapies in routine fracture liaison service (FLS) care and to explore clinical, functional, laboratory, and densitometric trajectories over follow-up. METHODS: Retrospective, single-center observational cohort study (Hospital Universitario de Navarra FLS, 2022-2024). Patients at imminent fracture risk (≥ 1 fragility fracture within 24 months before baseline) initiating romosozumab were identified; for each, one patient initiating denosumab, zoledronic acid, and teriparatide was selected by calendar time (same month ± 3 months). Outcomes were assessed at 3 and 12 months. Between-group comparisons used Kruskal-Wallis tests (continuous variables) and Fisher-Freeman-Halton exact tests (categorical variables); when significant, Dwass-Steel-Critchlow-Fligner pairwise tests were performed with Holm-Bonferroni correction. Given the small sample size and non-random treatment allocation, analyses were considered descriptive and hypothesis-generating. RESULTS: Sixty-eight patients were included (n = 17/group). Baseline profiles differed across treatments, consistent with indication-based prescribing; estimated fracture risk (FRAX/QFracture) was higher in anabolic-treated groups. At 12 months, scheduled-treatment completion was 100% among evaluable patients receiving denosumab, romosozumab, and zoledronic acid versus 52.9% with teriparatide; romosozumab versus teriparatide remained significant after Holm adjustment (p = 0.016). Incident fractures and adverse drug reactions were infrequent, and no significant between-group differences were observed in mortality, emergency visits, admissions, falls, fractures, or adverse drug reactions over follow-up. Treatment sequencing at 12 months differed significantly, with heterogeneous post-index regimens after romosozumab and after teriparatide. CONCLUSION: In this descriptive older adults FLS cohort, romosozumab recipients represented a higher-risk phenotype but showed broadly similar 12-month clinical trajectories compared with other therapies; monthly romosozumab showed high 12-month treatment completion and broadly similar short-term clinical trajectories to other treatment pathways, supporting its use in routine practice. Larger studies are required to determine comparative effectiveness and safety.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cedeno-Veloz BA, García AMR, Casajús A, et al. Romosozumab in older adults: real-world patterns in fracture liaison service cohort. Osteoporos Int. 2026. PMID: 42579011. doi:10.1007/s00198-026-08177-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。